家族性高コレステロール血症(II型高リポタンパク血症)治療薬の世界市場:治験レビュー

【英語タイトル】Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019

GlobalDataが出版した調査資料(GDT20FB0039)・商品コード:GDT20FB0039
・発行会社(調査会社):GlobalData
・発行日:2019年12月
・ページ数:304
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医薬品およびヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019
Summary

GlobalData’s clinical trial report, “Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2019″ provides an overview of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 20
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by End Point Status 26
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) 32
Nov 11, 2019: Amgen highlights data to be presented on Repatha at AHA 2019 Across Cardiovascular Portfolio 32
Nov 06, 2019: The Medicines company to present inclisiran data from ORION-9 and ORION-10 pivotal phase 3 clinical studies at American Heart Association Scientific Sessions 2019 33
Sep 17, 2019: Arrowhead reports initial data for cardiometabolic candidates 33
Sep 16, 2019: Arrowhead Pharmaceuticals presents initial top-line clinical data and preclinical data on RNAi Candidate ARO-APOC3 34
Clinical Trial Profile Snapshots 35
Appendix 303
Abbreviations 303
Definitions 303
Research Methodology 304
Secondary Research 304
About GlobalData 305
Contact Us 305
Source 306

List of Tables
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2019* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 10
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2019* 15
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2019* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 31

List of Figures
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2019* 15
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2019* 17
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 18
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 19
Proportion of Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2019* 20
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 21
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 22
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 23
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 24
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 25
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 26
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 27
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 28
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 29
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 30
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 31
GlobalData Methodology 304

★調査レポート[家族性高コレステロール血症(II型高リポタンパク血症)治療薬の世界市場:治験レビュー] (コード:GDT20FB0039)販売に関する免責事項を必ずご確認ください。
★調査レポート[家族性高コレステロール血症(II型高リポタンパク血症)治療薬の世界市場:治験レビュー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆